Neuroscience · global
A Tube of Blood Reveals Alzheimer’s Risk, as p-tau217 Research Pushes Prevention Trials Earlier
Blood biomarkers are shifting the Alzheimer’s question from “whether someone already has dementia” to “who may develop symptoms in the next few years”; but this risk map is not yet a pass for healthy people to self-screen.
The hardest moment to address in Alzheimer’s disease is often not after symptoms appear, but during the stage when the disease has been quietly accumulating in the brain for years while the clinical picture remains calm. A newly published study in JAMA, also presented at the Alzheimer’s Association International Conference in London, shows that a blood test called p-tau217 may help identify older adults who appear healthy but have a higher risk of developing cognitive impairment over the next 5 to 10 years.
The study, conducted by a Mass General Brigham team, analyzed data from 2,684 older adults who had no symptoms when they enrolled in a long-term Alzheimer’s study. Participants received a p-tau217 blood test at the start of the study and then underwent annual cognitive follow-up; from the earliest enrollment in 2004 through last year, about 478 people developed cognitive impairment.
The results showed that asymptomatic participants with very high p-tau217 levels had a 38% risk of developing cognitive impairment within 5 years, rising to 78% over 10 years. By contrast, those with very low p-tau217 levels also had lower risk over the same time frames. This means blood testing is not only being used, as in the past, to help determine whether people who already have cognitive problems may have Alzheimer’s disease, but is also starting to be placed into the idea of risk stratification “before disease onset.”
p-tau217 measures a phosphorylated form of the tau protein. The typical pathology of Alzheimer’s disease includes amyloid plaques and tau tangles; many people may have amyloid buildup in the brain without necessarily progressing to dementia. Researchers believe p-tau217 may provide a signal closer to the disease process, reflecting whether tau pathology has moved in a more dangerous direction after amyloid accumulation.
Background Context
This advance matters for clinical research because Alzheimer’s treatment is gradually moving earlier. Anti-amyloid drugs have entered treatment for the early course of disease, and trials to prevent or delay onset are also underway. If drugs can truly intervene before symptoms appear in the future, researchers will need cheaper, more scalable ways to identify the people most likely to benefit from trials, rather than relying only on expensive or more invasive brain imaging and cerebrospinal fluid tests.
But the study also clearly leaves boundaries. Scholars involved in the commentary noted that the proportion of participants with a full 10 years of follow-up was smaller, so the confidence in the 10-year risk estimate is not as strong as for 5 years; older adults may also die from other diseases, or develop vascular dementia because of cardiovascular-related problems, making prediction based on a single blood marker more complex. In other words, p-tau217 can help map population risk, but it is still not enough to draw conclusions about an individual’s fate.
For generally healthy adults, this is not a reason to immediately seek testing. The research team and experts not involved in the study both emphasized that, before there is a clearly established preventive treatment that can be acted on based on test results, p-tau217 is better suited for clinical trial recruitment and study design than for routine screening. The real question raised by this tube of blood is whether medicine can find a point during the silent phase of disease at which it can intervene responsibly; the answer still needs to be filled in by treatment trials, long-term follow-up, and clinical standards together.